The role of liposome-protamine-DNA nanoparticles containing CpG oligodeoxynucleotides in the course of infection induced by Leishmania major in BALB/c mice

Experimental Parasitology

Volumn 132, Issue 3, 2012, Pages 313-319

  Alavizadeh, Seyedeh Hoda ^a   Badiee, Ali ^a   Khamesipour, Ali ^c   Jalali, Seyed Amir ^a   Firouzmand, Hengameh ^a   Abbasi, Azam ^a   Jaafari, Mahmoud Reza ^a,b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CpG ODN; Immune response; Leishmania major; Leishmanization; LPD nanoparticles

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; DNA; IMMUNOGLOBULIN G2A; LIPOSOME; NANOPARTICLE; PROTAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE COURSE; DRUG DELIVERY SYSTEM; FEMALE; IMMUNOGENICITY; IMMUNOMODULATION; LEISHMANIASIS; MOUSE; NONHUMAN; PARASITE IMMUNITY; PARASITE LOAD; PARTICLE SIZE; PRIORITY JOURNAL; TH1 CELL; ZETA POTENTIAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; CELLS, CULTURED; DNA; FEMALE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LIPOSOMES; LYMPH NODES; MICE; MICE, INBRED BALB C; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; PROTAMINES; SPLEEN;

LEISHMANIA MAJOR; MUS;

EID: 84867328872     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2012.06.014     Document Type: Article

References (45)

1. Badiee A., Jaafari M.R., Samiei A., Soroush D., Khamesipour A. Coencapsulation of CpG oligodeoxynucleotides with recombinant leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin. Vaccine Immunol. 2008, 15:668-674.
2. Chen W., Yan W., Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol. Immunother. 2008, 57:517-530.
3. Chen Y.X., Qiao W.H., Liu D.L., Li Z.S. The mechanism and efficiency affecting factor of cationic liposome transfection. Sheng Wu Gong Cheng Xue Bao 2007, 23:776-780.
4. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 1997, 186:1623-1631.
5. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006, 19:111.
6. Cui Z., Han S.J., Vangasseri D.P., Huang L. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol. Pharm. 2005, 2:22-28.
7. Cui Z., Huang L. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: Therapeutic effect against cervical cancer. Cancer Immunol. Immunother. 2005, 54:1180-1190.
8. Dileo J., Banerjee R., Whitmore M., Nayak J.V., Falo L.D., Huang L. Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol. Ther. 2003, 7:640-648.
9. Gursel I., Gursel M., Ishii K.J., Klinman D.M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol. 2001, 167:3324-3328.
10. Hadighi R., Mohebali M., Boucher P., Hajjaran H., Khamesipour A., Ouellette M. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant leishmania tropica parasites. PLoS Med. 2006, 3:e162.
11. Hejazi, H., 2010. The Role of liposomal CpG ODN on the course of l. major infection in balb/c mice. Iranian J. Parasitol. 5.
12. Jaafari M.R., et al. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 2007, 25:6107-6117.
13. Kedzierski L., Zhu Y., Handman E. Leishmania vaccines: progress and problems. Parasitology 2006, 133(Suppl):S87-112.
14. Khamesipour A., et al. Leishmanization: Use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 2005, 23:3642-3648.
15. Khamesipour A., Rafati S., Davoudi N., Maboudi F., Modabber F. Leishmaniasis vaccine candidates for development: a global overview. The Ind. J. Med. Res. 2006, 123:423-438.
16. Khatami, A., Firooz, A., Gorouhi, F., Dowlati, Y., 2007. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. Journal of the American Academy of Dermatology 57, 335. e331-335. e329.
17. King C., et al. Cytokine control of parasite-specific anergy in human lymphatic filariasis. Preferential induction of a regulatory T helper type 2 lymphocyte subset. J. Clin. Invest. 1993, 92:1667.
18. Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 2003, 2:305-315.
19. Klinman D.M., Currie D., Gursel I., Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 2004, 199:201-216.
20. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA 1996, 93:2879-2883.
21. Krieg A.M. Immune effects and mechanisms of action of CpG motifs. Vaccine 2000, 19:618-622.
22. Krieg A.M., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
23. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 2003, 270:1628-1644.
24. Laabs E.M., Wu W., Mendez S. Vaccination with live Leishmania major and CpG DNA promotes interleukin-2 production by dermal dendritic cells and NK cell activation. Clin. Vaccine Immunol. 2009, 16:1601-1606.
25. Li S., Huang L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther. 1997, 4:891-900.
26. Li S., Rizzo M.A., Bhattacharya S., Huang L. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther. 1998, 5:930-937.
27. Li S.D., Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim. Biophys. Acta 2009, 1788:2259-2266.
28. Li Y., Simons F.E.R., Jay F.T., HayGlass K.T. Allergen-driven limiting dilution analysis of human IL-4 and IFN-γ production in allergic rhinitis and clinically tolerant individualsz. Int. Immunol. 1996, 8:897-904.
29. Mauel J. Vaccination Against Leishmania Infections. Current Drug Targets-Immune, Endocrine & Metabolic Disorders 2002, 2:201-226.
30. Mendez S., et al. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability. Infect. Immun. 2003, 71:5121-5129.
31. Menon J.N., Bretscher P.A. Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge. Eur. J. Immunol. 1996, 26:243-249.
32. Modabber F., Buffet P., Torreele E., Milon G., Croft S. Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biol. Dis. 2007, 6:3.
33. Moll H., Flohe S., Rollinghoff M. Dendritic cells in Leishmania major-immune mice harbor persistent parasites and mediate an antigen-specific T cell immune response. Eur. J. Immunol. 1995, 25:693-699.
34. Nadim A., Javadian E., Tahvildar-Bidruni G., Ghorbani M. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bulletin de la société de Pathology Exotique et de ses filiales 1983, 76:377-383.
35. Noazin S., et al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine 2009, 27:4747-4753.
36. Noazin S., et al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 2008, 26:6759-6767.
37. Palatnik de Sousa C.B., Silva-Antunes I., Morgado A.d.A., Menz I., Palatnik M., Lavor C. Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune® in Brazilian endemic areas. Vaccine 2009, 27:3505-3512.
38. Papierok G., Hugnet C., Bourdoiseau G., Lemesre J. A-15 Le Cani Leish®, un vaccin contre le réservoir canin de la leishmaniose: des résultats prometteurs pour un futur vaccin humain. Médecine et Maladies Infectieuses 2008, 38. S136-S136.
39. Rhee E.G., et al. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+and CD8+T Cell responses and protection against leishmania major infection. J. Exp. Med. 2002, 195:1565-1573.
40. Scott P., Pearce E., Natovitz P., Sher A. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. J. Immunol. 1987, 139:221-227.
41. Sergiev V. Control and prophylaxis of cutaneous leishmaniasis in the middle Asia republics of the former USSR. Bulletin de la Société française de parasitologie 1992, 10:183-187.
42. Sharifi I., et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. The Lancet 1998, 351:1540-1543.
43. Tam Y.K. Liposomal encapsulation enhances the activity of immunostimulatory oligonucleotides. Future Lipidology 2006, 1:35-46.
44. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies I. Data analysis. J. Immunol. 1981, 126:1614-1619.
45. Titus R.G., Marchand M., Boon T., Louis J.A. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 1985, 7:545-555.